期刊文献+

老年心衰患者血浆尾加压素Ⅱ的浓度及运动训练的影响 被引量:10

Concentration of plasma Urotensin Ⅱ in aged patients with chronic heart failure and the effects of exercise training on it
下载PDF
导出
摘要 目的:测定老年慢性心力衰竭患者血浆尾加压素Ⅱ(U rotens inⅡ,UⅡ)的浓度,探讨血浆UⅡ水平与心功能的关系以及运动训练之影响。方法:分别测定118例心衰和48例非心衰病人以及30名正常人血浆UⅡ和脑钠肽(BNP)水平,对其进行相关比较。并在对心衰病人实施运动训练后,测定其治疗后血浆UⅡ和BNP水平,经心脏超声检测左室射血分数(LVEF)。结果:伴有心衰的心脏病患者血浆UⅡ水平(3.29±1.56 pg/m l)和不伴有心衰的心脏病患者血浆UⅡ水平(4.40±1.99 pg/m l)均明显低于正常人血浆UⅡ水平(7.55±1.62 pg/m l),P<0.05或P<0.01;心衰患者降低更为明显,并且随心功能不全的加重而下降(P均<0.01);血浆UⅡ水平与心功能分级和血浆BNP水平呈负相关(分别r=-0.313和r=-0.308,P<0.01),与LVEF呈正相关(r=0.304,P<0.05);训练组患者治疗后血浆UⅡ水平明显增加而血浆BNP水平则显著降低(P<0.01),与非训练组有显著差异(P<0.05)。结论:血浆UⅡ水平随心功能不全加重和血浆BNP水平的增加而降低,运动训练可升高血浆UⅡ水平,改善心功能。这提示血浆UⅡ水平可作为判断心衰严重程度和临床评价心衰治疗效果的生物学指标。 Objective: To observe the changes of plasma Urotensin Ⅱ (U Ⅱ ) and brain natriuretic peptide (BNP) in the aged patients with chronic heart failure (CHF), and effect of exercise training on plasma U Ⅱ level. Methods: The levels of plasma U Ⅱ and BNP were determined by radioimmunoassay in 118 patients with CHF, 48 patients without heart failure and 30 control normal subjects. After treatments, the levels of plasma U Ⅱ and BNP levels were also observed between the patients with exercise training and without exercise training. Left ventricular fraction (LVEF) was measured by echocardiography in all subjects. Results: The plasma U Ⅱ level was significantly decreased in patients with CHF (3.29±1.59 pg/ml) and without heart failure (4.40±1.99 pg/ml) compared with control subjects (7.55±1.62 pg/ml), P〈0.05 or P〈0. 01, The plasma U Ⅱ level was significantly lower in the patients with CHF than that of without CHF (P〈0. 05). The decreased plasma U Ⅱ level were parallel with the severity of CHF. The plasma U Ⅱ level was negative correlation with cardiac function grade (r= —0. 313, P〈0.01) and the plasma BNP levels (r=—0. 308, P〈0. 01) . There was a significant positive correlation between plasma level of U Ⅱ and LVEF (r= 0. 304, P〈0.05) . Plasma U Ⅱ level increaced, plasma BNP level decreased after treatment in all patients; there were significantly different between the patients with exercise training and without exercise training (P〈0. 05). Conclusion: The decreased plasma U Ⅱ level and the increased plasma BNP level were parallel with the severity of CHF. Exercise training can improve cardiac function, increase plasma U Ⅱ level. These results suggest that the plasma U Ⅱ level in CHF patients may serve as an index of the severity of CHF and the assessment for treatment effect.
出处 《心血管康复医学杂志》 CAS 2006年第5期424-426,423,共4页 Chinese Journal of Cardiovascular Rehabilitation Medicine
基金 首都发展基金项目(项目编号2002-3156)
关键词 心力衰竭 充血性 尾加压素Ⅱ 脑钠肽 运动疗法 Heart failure, congestive UrotensinⅡ Natriuretie peptide, brain Exercise therapy
  • 相关文献

参考文献10

  • 1Phalipon A,folgori A,Arondel,et al.Induction of anti-carbohydrate antibody by library-selected peptide mimics[J].Eur J Immunol,1997,27(10):2620-2625. 被引量:1
  • 2Ames RS,Sarnu HM,Chambers JK,et al.Human urotensin Ⅱ is a potent vassocontrictor and agonist for the orphan receptor GPR14[J].Nature,1999,401:282-286. 被引量:1
  • 3Russell FD,Molenaar P,O'Brien DM.Cardiostimulant effect of urotensin Ⅱ in human heart in vitro[J].Br J Pharmacol,2001,132:5-9. 被引量:1
  • 4钟萍,李志樑,吴宏超,唐朝枢,陆青.充血性心力衰竭患者血浆尾加压素Ⅱ变化的临床研究[J].第一军医大学学报,2003,23(2):121-123. 被引量:19
  • 5Douglas SA,Ohlstein EH.Human urotensin Ⅱ,the most potent mammalian vasoconstrictor identified to date,as a therapeutic target for the management of cardiovascular disease[J].Trends Cardiovasc Med,2000,10(6):229-237. 被引量:1
  • 6Ng LL,Loke I,O'Brein RJ,et al.Plasma urotensin Ⅱ in human systolic heart failure[J].Circulation 2002,106(23):2877. 被引量:1
  • 7Russell FD,Meyers D,Galbraith AJ,et al.Elevated plasma levels of human urotensin-Ⅱ immunoreactivity in congestive heart failure[J].Am J Physiol Heart Circ Physiol,2003,285(4):H1576. 被引量:1
  • 8Dschietzig T,Richter C,Bartsch C,et al.Flow-induced pressure differentially regulates endothelin-1,urotensinⅡ,adrenomedulin,and relaxin in pulmonary vascular endothelium[J].Biochem Biophys Res Commun,2001,289:245-251. 被引量:1
  • 9Finkel MS,Oddis CV,Jacob,TD,et al.Negative inotropic effects of cytokines on the heart mediated by nitric oxide[J].Science,1992,257:387-389. 被引量:1
  • 10李玲,袁文俊,潘秀颉,王伟忠,邱景伟,唐朝枢,唐朝枢.尾加压素对新生大鼠心肌细胞一氧化氮合成的影响[J].生理学报,2002,54(4):307-310. 被引量:7

二级参考文献20

  • 1[1]Coulouarn Y, Lihrman I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H. Cloning of cDNA encoding the urotensinⅡprecursor in frog and human reveals intense expression of the urotensinⅡgene in motoneurons of the spinal cord. Proc Natl Acad Sci USA, 1998, 95:15803~15808. 被引量:1
  • 2[2]Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AN, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, Mcnulty DE, Ellis CE, Elshouragy NA, Shabon U, Trill JJ, Hay DWP, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-Ⅱis a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 1999, 401(6750):282~286. 被引量:1
  • 3[3]Russell FD, Molenaar P, O′Brien DM. Cardiostimulant effects of urotensin-Ⅱin human heart in vitro. Br J Pharmacol, 2001,132:5~9. 被引量:1
  • 4[4]Douglas SA,Ohlstein EH.Human urotensin-Ⅱ,the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med, 2000, 10:229~237. 被引量:1
  • 5[5]Kumar A, Brar R, Wang P, Dee L, Skorupa G, Khadour F, Schulz R, Parrillo JE. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol, 1999,276(1 Pt 2):R265~R276. 被引量:1
  • 6[6]Maclean MR, Alexander D, Seirrar A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, Pollard K. Contractile responses to human urotensin-Ⅱin rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol, 2000,130:201~204. 被引量:1
  • 7[7]Gray GA, Jones MR, Sharif I. Human urotensinⅡ increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci, 2001,69:175~180. 被引量:1
  • 8[8]Katano Y, Ishihata A, Aita T, Ogaki T, Horie T. Vasodilator effect of urotensinⅡ, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol, 2000,402(1-2):R5~R7. 被引量:1
  • 9[9]Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-Ⅱ in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol, 2000,131:1262~1274. 被引量:1
  • 10[10]Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science, 1992,257:387~389. 被引量:1

共引文献21

同被引文献415

引证文献10

二级引证文献141

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部